AGMB AgomAb Therapeutics NV
Healthcare · Biological Products, (No Diagnostic Substances) · Market cap: not available
–
Bought and sold by quarter, last 5 years
Open-market purchases and sales by this company's insiders, in dollars, last 5 years
| Quarter | Bought | Sold |
|---|---|---|
| 2022-Q1 | $0 | $0 |
| 2022-Q2 | $0 | $0 |
| 2022-Q3 | $0 | $0 |
| 2022-Q4 | $0 | $0 |
| 2023-Q1 | $0 | $0 |
| 2023-Q2 | $0 | $0 |
| 2023-Q3 | $0 | $0 |
| 2023-Q4 | $0 | $0 |
| 2024-Q1 | $0 | $0 |
| 2024-Q2 | $0 | $0 |
| 2024-Q3 | $0 | $0 |
| 2024-Q4 | $0 | $0 |
| 2025-Q1 | $0 | $0 |
| 2025-Q2 | $0 | $0 |
| 2025-Q3 | $0 | $0 |
| 2025-Q4 | $0 | $0 |
| 2026-Q1 | $0 | $0 |
| 2026-Q2 | $0 | $0 |
| 2026-Q3 | $0 | $0 |
| 2026-Q4 | $503.5K | $0 |
Bought$503.5K8 buy days
Sold$00 sell days
Net insider flow+$503.5Knet buying · 5 years
Latest trade2026-11-05Epstein David R
| Date | Side | Insider | Role | Shares | Avg price | Value | Trades |
|---|---|---|---|---|---|---|---|
| 2026-11-05 | Buy | Epstein David R | Director | 15,000 | $6.90 | $103.5K | 3 |
| 2026-10-21 | Buy | Epstein David R | Director | 10,000 | $8.88 | $88.8K | 2 |
| 2026-10-08 | Buy | Epstein David R | Director | 5,000 | $8.90 | $44.5K | 1 |
| 2026-10-06 | Buy | Kemula Pierre Thadee Victor | CFO | 10,000 | $8.59 | $85.9K | 3 |
| 2026-10-06 | Buy | Epstein David R | Director | 5,000 | $8.70 | $43.5K | 1 |
| 2026-10-06 | Buy | Knotnerus Tim Jasper | CEO | 5,000 | $8.70 | $43.5K | 1 |
| 2026-10-05 | Buy | Knotnerus Tim Jasper | CEO | 6,000 | $8.48 | $50.9K | 1 |
| 2026-10-05 | Buy | Epstein David R | Director | 5,000 | $8.57 | $42.8K | 1 |
Who the insiders are, last 5 years
Everyone who bought or sold this company's shares on the open market in the last 5 years, biggest first.
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Epstein David R | Director | $323.2K | $0 | 2026-11-05 |
| Knotnerus Tim Jasper | CEO | $94.4K | $0 | 2026-10-06 |
| Kemula Pierre Thadee Victor | CFO | $85.9K | $0 | 2026-10-06 |
Past buying clusters
A cluster is a run of purchases by three or more insiders. Returns are the stock's return minus its benchmark's (IWM for small companies, SPY otherwise), from the first open after the run became a cluster. Past results, not a forecast.
| Window | Insiders | Total | Score | 21 days vs benchmark | 63 days vs benchmark | 126 days vs benchmark | Status |
|---|---|---|---|---|---|---|---|
| 2026-10-05 → 2026-11-05 | 3 | $503.5K | 64 | -16.6% (-22.1% raw) | – | – | active |
Yahoo Finance data, delayed, loaded through this server. Informational only; not investment advice.